Sentiment Report: Allergan Inc (NYSE:AGN)

Allergan plc (NYSE:AGN) Logo

Sentiment for Allergan Inc (NYSE:AGN)

Allergan Inc (NYSE:AGN) institutional sentiment decreased to 0 in 2019 Q2. Its down -2.00, from 2 in 2019Q1. The ratio turned negative, as 0 active investment managers increased or started new positions, while 4 reduced and sold their stock positions in Allergan Inc. The active investment managers in our partner’s database now hold: 20,340 shares, down from 25,607 shares in 2019Q1. Also, the number of active investment managers holding Allergan Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 3 Increased: 0 New Position: 0.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $54.50 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

The stock decreased 0.13% or $0.21 during the last trading session, reaching $166.14. About 2.12M shares traded. Allergan plc (NYSE:AGN) has declined 12.77% since September 13, 2018 and is downtrending. It has underperformed by 12.77% the S&P500.

Analysts await Allergan plc (NYSE:AGN) to report earnings on October, 29. They expect $4.21 EPS, down 0.94 % or $0.04 from last year’s $4.25 per share. AGN’s profit will be $1.38B for 9.87 P/E if the $4.21 EPS becomes a reality. After $4.38 actual EPS reported by Allergan plc for the previous quarter, Wall Street now forecasts -3.88 % negative EPS growth.

Mitchell Mcleod Pugh & Williams Inc holds 0.46% of its portfolio in Allergan plc for 3,982 shares. Callahan Advisors Llc owns 12,774 shares or 0.38% of their US portfolio. Moreover, Cullinan Associates Inc has 0.02% invested in the company for 2,000 shares. The Pennsylvania-based Staley Capital Advisers Inc has invested 0.02% in the stock. Gemmer Asset Management Llc, a California-based fund reported 145 shares.

Allergan plc (NYSE:AGN) Ratings Coverage

Ratings analysis reveals 40% of Allergan’s analysts are positive. Out of 10 Wall Street analysts rating Allergan, 4 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $13300 while the high is $18900. The stock’s average target of $166.50 is 0.22% above today’s ($166.14) share price. AGN was included in 25 notes of analysts from March 20, 2019. Piper Jaffray maintained Allergan plc (NYSE:AGN) on Wednesday, March 20 with “Hold” rating. The rating was downgraded by Leerink Swann on Thursday, July 18 to “Market Perform”. The firm has “Buy” rating by UBS given on Wednesday, April 3. UBS maintained Allergan plc (NYSE:AGN) rating on Thursday, September 12. UBS has “Buy” rating and $18900 target. Raymond James maintained the stock with “Outperform” rating in Thursday, May 9 report. The rating was maintained by RBC Capital Markets on Wednesday, May 8 with “Sector Perform”. Credit Suisse maintained Allergan plc (NYSE:AGN) rating on Monday, March 25. Credit Suisse has “Hold” rating and $155 target. Mizuho maintained Allergan plc (NYSE:AGN) on Tuesday, June 25 with “Buy” rating. The rating was maintained by UBS on Thursday, May 9 with “Buy”. The rating was maintained by Stifel Nicolaus with “Hold” on Monday, March 25.

More notable recent Allergan plc (NYSE:AGN) news were published by: which released: “Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab) – PRNewswire” on August 22, 2019, also with their article: “Allergan plc’s (NYSE:AGN) Profit Outlook – Yahoo Finance” published on June 15, 2019, published: “Allergan settles federal opioid litigation for $5M – Seeking Alpha” on August 30, 2019. More interesting news about Allergan plc (NYSE:AGN) were released by: and their article: “Allergan (AGN) Receives FDA Approval of Juvederm VOLUMA XC For Mid-Face Injection Via Cannula –” published on September 03, 2019 as well as‘s news article titled: “How Will Johnson & Johnson’s Opioid Case Ruling Impact Big Pharma Stocks? – The Motley Fool” with publication date: September 05, 2019.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.